ng, peptide-based therapeutics, and beyond, it’s no wonder that Bracken co-founder and Managing Partner Dr. Jim Gilligan is also leading the way in therapeutic psychedelic drug development. With 35+ years of expertise, Jim’s cutting-edge work is reshaping our approach to mental health and chronic pain management. This integrated approach combines clinical insight with scientific innovation, turning psychedelic research into practical, impactful treatments.

In this episode of Fractals, join Jim and host Colin Miller as they explore:

The groundbreaking science behind psilocybin-assisted therapy and its potential to revolutionize mental health and chronic pain treatment.
The essential role of clinical trials in validating psychedelic drugs, and insights into navigating the complex regulatory landscape.
Strategies for biotech startups to attract investors, blending robust clinical data with a compelling commercial strategy.
How investing in the future of science means supporting areas with high clinical impact, sustainable healthcare solutions, transformative research, and the growth of young scientists.

Listen to Fractals: Life Science Conversations via your preferred podcast service, and contact us today to learn more about working with Jim and Bracken’s team of expert consultants.

1e:T5fb,

With expertise in pharmacology, due diligence, strategic planning, peptide-based therapeutics, and beyond, it’s no wonder that Bracken co-founder and Managing Partner Dr. Jim Gilligan is also leading the way in therapeutic psychedelic drug development. With 35+ years of expertise, Jim’s cutting-edge work is reshaping our approach to mental health and chronic pain management. This integrated approach combines clinical insight with scientific innovation, turning psychedelic research into practical, impactful treatments.

In this episode of Fractals, jo